CN102274423B - 一种治疗焦虑症的药剂 - Google Patents
一种治疗焦虑症的药剂 Download PDFInfo
- Publication number
- CN102274423B CN102274423B CN 201110250475 CN201110250475A CN102274423B CN 102274423 B CN102274423 B CN 102274423B CN 201110250475 CN201110250475 CN 201110250475 CN 201110250475 A CN201110250475 A CN 201110250475A CN 102274423 B CN102274423 B CN 102274423B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicament
- root
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 230000036506 anxiety Effects 0.000 title abstract description 7
- 241000489492 Arisaema Species 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- 210000000582 semen Anatomy 0.000 claims description 10
- 241000244155 Taenia Species 0.000 claims description 5
- 210000000941 bile Anatomy 0.000 claims description 5
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 5
- 240000001972 Gardenia jasminoides Species 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗焦虑症的药剂，它是由下述重量配比的物质制成：牛膝、麦冬、竹茹、酸枣仁、枳实、黄芩、牡丹皮、桔梗、栀子、桃仁、海浮石、甘草、百合、胆南星、赤芍和石菖蒲。本发明所述的治疗焦虑症的药剂的全部成分都是天然材料，安全性较好，适于在临床上大规模推广。
Description
技术领域
本发明涉及医药领域，具体来说涉及一种治疗焦虑症的药剂。
背景技术
焦虑症又称焦虑性神经症，是以广泛性焦虑症(慢性焦虑症)和发作性惊恐状态(急性焦虑症)为主要临床表现，常伴有头晕、胸闷、心悸、呼吸困难、口干、尿频、尿急、出汗、震颤和运动性不安等症，其焦虑并非由实际威胁所引起，或其紧张惊恐程度与现实情况很不相称。
目前临床上多采用化学药物进行治疗，但是由于化学药物的毒副作用相对校对，因为在治疗效果上存在一些问题。
本发明的目的是提供一种治疗焦虑症的药剂。
为了实现本发明的目的，本发明提供一种治疗焦虑症的药剂，它是由下述重量配比的物质制成：牛膝3-5份、麦冬1-3份、竹茹1-3份、酸枣仁2-5份、枳实0.1-0.5份、黄芩1-3份、牡丹皮2-5份、桔梗1-3份、栀子3-5份、桃仁3-5份、海浮石1-3份、甘草5-8份、百合1-3份、胆南星1-3份、赤芍3-5份和石菖蒲1-3份。
优选地，本发明所述的治疗焦虑症的药剂是由下述重量配比的物质制成：牛膝3份、麦冬2份、竹茹3份、酸枣仁2份、枳实0.3份、黄芩2份、牡丹皮4份、桔梗2份、栀子4份、桃仁3份、海浮石2份、甘草6份、百合2份、胆南星2份、赤芍4份和石菖蒲1份。
优选地，本发明的药剂可以为片剂、分散片、胶囊剂或汤剂。可以采用本领域技术人员熟知的方法来进行药剂的制备。根据需要，可以加入各种药学上可接受的载体。所述的载体包括药学领域常规的稀 释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂等。本发明的药剂在制备时，可选择的填充剂有：淀粉、糖粉、磷酸钙、糊精、微晶纤维素、乳糖、预胶化淀粉、甘露醇等；可选择的粘合剂有：羧甲基纤维素钠、PVP-K30、羟丙基纤维素、淀粉浆、甲基纤维素、乙基纤维素、羟丙基甲基纤维素、胶化淀粉等；可选择的崩解剂有：干淀粉、交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠、低取代羟丙基纤维素等；可选择的润滑剂有：硬脂酸镁、滑石粉、十二烷基硫酸钠、微粉硅胶等。
本发明所述的治疗焦虑症的药剂的全部成分都是天然材料，安全性较好，适于在临床上大规模推广。
具体实施方式
下面通过实施例进一步说明本发明。应该理解的是，本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。除非另有说明，否则本发明中的百分数是重量百分数。
实施例
称取牛膝30克、麦冬20克、竹茹30克、酸枣仁20克、枳实3克、黄芩20克、牡丹皮40克、桔梗20克、栀子40克、桃仁30克、海浮石20克、甘草60克、百合20克、胆南星20克、赤芍40克和石菖蒲10克，粉碎，过80目筛。然后称取糖粉50克，过80目筛，和上述原料混合。用3重量％的HPMC水溶液作粘合剂制软材，制粒(用16目尼龙筛制粒二遍)，在60℃下干燥2-3个小时，用16目的尼龙筛整粒。再加入40克的羧甲基淀粉钠和2克的硬脂酸镁，混匀，用直径14mm的冲头压片100片。
实验例
一、患者资料
患者共50例，其中男25例，女25例，平均年龄39岁，平均病程2.5年。
焦虑症患者纳入标准临床上有焦虑症症状的表现，符合《中国精神障碍分类与诊断标准》(中华医学会精神科分会.中国精神障碍分类与诊断标准.3版.济南：山东科学技术出版社，2001：105)焦虑症诊断标准，Hamilton焦虑量表(HAMA)14项总分≥14分(张明圆.精神科量表评定手册.长沙：湖南科学技术出版社.1993：34-137.121-126.198-202)。2周内未使用抗焦虑药或精神药物。
排除标准(1)排除严重的躯体和神经系统疾病(如甲状腺机能亢进、冠心病、高血压病、脑血管意外等)；(2)酒精和药物依赖者；(3)正在服用抗焦虑剂及精神药物者；(4)孕妇及哺乳期妇女。
二、治疗方法
使用实施例1中制备片剂对于上述患者进行治疗，一日两次，每次一片。以21天为一个疗程，连续进行两个疗程。
三、评分标准
采用HAMA量表进行评定，在治疗前和治疗第1、2、4、6周末各评定1次。6周末按HAMA减分率评定疗效。量表由3名精神科医师评定，量表一致性测验的平均相关系数为0.83。
四、疗效标准
按照中华医学会神经精神科学会拟定的4级标准。治愈：在治疗第6周末，HAMA减分率＞75％；显著进步：HAMA减分率50％～75％；进步：HAMA减分率25％～49％；无效：HAMA减分率＜25％。
五、结果
50例患者经治疗后全部符合治愈标准。
六、不良反应
对于50例患者在治疗过程中进行跟踪观察，未发现明显的不良反应。
Claims (2)
1.一种治疗焦虑症的药剂，其特征在于，它是由下述重量配比的物质制成：牛膝3-5份、麦冬1-3份、竹茹1-3份、酸枣仁2-5份、枳实0.1-0.5份、黄芩1-3份、牡丹皮2-5份、桔梗1-3份、栀子3-5份、桃仁3-5份、海浮石1-3份、甘草5-8份、百合1-3份、胆南星1-3份、赤芍3-5份和石菖蒲1-3份。
2.根据权利要求1所述的治疗焦虑症的药剂，其特征在于，它是由下述重量配比的物质制成：牛膝3份、麦冬2份、竹茹3份、酸枣仁2份、枳实0.3份、黄芩2份、牡丹皮4份、桔梗2份、栀子4份、桃仁3份、海浮石2份、甘草6份、百合2份、胆南星2份、赤芍4份和石菖蒲1份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110250475 CN102274423B (zh) | 2011-08-29 | 2011-08-29 | 一种治疗焦虑症的药剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110250475 CN102274423B (zh) | 2011-08-29 | 2011-08-29 | 一种治疗焦虑症的药剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102274423A CN102274423A (zh) | 2011-12-14 |
| CN102274423B true CN102274423B (zh) | 2013-04-24 |
Family
ID=45100366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110250475 Expired - Fee Related CN102274423B (zh) | 2011-08-29 | 2011-08-29 | 一种治疗焦虑症的药剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102274423B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727741B (zh) * | 2012-07-18 | 2013-08-07 | 宋克侠 | 一种治疗焦虑症的药剂 |
| US11058740B2 (en) * | 2017-04-18 | 2021-07-13 | Sung Kyun Biotech Co., Ltd. | Composition for preventing, alleviating or treating stress diseases, containing Platycodon grandiflorum extract as active ingredient |
-
2011
- 2011-08-29 CN CN 201110250475 patent/CN102274423B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102274423A (zh) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101607059B (zh) | 一种中药组合物在制备治疗和预防辐射线损伤的药物中的应用 | |
| CN104666951A (zh) | 一种治疗产后风月子病的中药组合物 | |
| CN102657821B (zh) | 一种治疗卵巢囊肿的药剂 | |
| CN102274423B (zh) | 一种治疗焦虑症的药剂 | |
| CN1302796C (zh) | 治疗妇女亚健康疲劳综合症的中药制剂及其制备方法 | |
| CN111214637A (zh) | 一种中药组合物及其制备方法和药用用途 | |
| CN101810826B (zh) | 一种治疗肝癌的中药组合物 | |
| CN101584796A (zh) | 一种中药组合物在制备治疗抑郁症的药物中的应用 | |
| CN102698064B (zh) | 一种治疗更年期综合征的药剂 | |
| CN106420970A (zh) | 一种治疗卵巢早衰的药物组合物 | |
| CN102526473B (zh) | 一种治疗慢性乙型病毒性肝炎的药剂 | |
| CN102698094B (zh) | 一种治疗女性抑郁症的药剂 | |
| CN102641418B (zh) | 一种治疗偏头痛的药剂 | |
| CN102266482B (zh) | 一种治疗躁狂症的药剂 | |
| CN103251893B (zh) | 一种治疗男性不育的中药组合物 | |
| CN102327408B (zh) | 一种治疗骨质疏松的药剂 | |
| CN107158286B (zh) | 一种用于治疗雾霾致呼吸道损伤诱发症的中药组合物及其制备方法 | |
| CN104491318A (zh) | 一种治疗哮喘的中药制剂及其制备方法 | |
| CN104258037A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
| CN100360162C (zh) | 一种具有增强性功能、增强体力和抗疲劳作用的中药组合物 | |
| CN102727741B (zh) | 一种治疗焦虑症的药剂 | |
| CN102058668A (zh) | 一种治疗原发性血小板减少的中药制剂 | |
| CN106692645A (zh) | 一种用于治疗淋巴结核病的中药及其制备方法 | |
| CN104189846A (zh) | 一种用作放化疗增敏剂的中药组合物及其制备方法 | |
| CN102784377B (zh) | 一种治疗男性无精少精的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG Free format text: FORMER OWNER: RUAN JIUQIONG Effective date: 20130807 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272051 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130807 Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin Address before: 272051 Shandong province Jining city wear Zhuangji wearing No. 1 Shandong Road, Jining city mental hospital Patentee before: Ruan Jiuqiong |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Peng Inventor before: Ruan Jiuqiong Inventor before: Li Zunqing |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170417 Address after: 414000 Yunxi Industrial Park, Yunxi District, Hunan, Yueyang Patentee after: Yueyang Pengcheng Technology Development Co., Ltd. Address before: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee before: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20170829 |